Sumitomo Pharma Co.

4506.TSE

17.39 USD

-0.53

-2.96%

Overview

Last close

17.39 usd

Market cap

6.91B usd

52 week high

18.46 usd

52 week low

2.66 usd

Target price

13.65 usd

Valuation

P/E

7.0621

Forward P/E

20.202

Price/Sales

2.454

Price/Book Value

4.1137

Enterprise Value

8.27B usd

EV/Revenue

2.9363

EV/EBITDA

8.2825

Key financials

Revenue TTM

2.82B usd

Gross Profit TTM

1.74B usd

EBITDA TTM

880.42M usd

Earnings per Share

2.46 usd

Dividend

N/A usd

Total assets

5.26B usd

Net debt

1.52B usd

About

Sumitomo Pharma Co., Ltd. Manufactures, purchases, and sells pharmaceutical products for medical treatment in Japan, North America, and Asia. It offers therapeutic agents for parkinson's disease, type 2 diabetes, advanced prostate cancer, uterine fibroids and endometriosis, overactive bladder, and pediatric congenital athymia. The company also provides atypical antipsychotic, generic products, antiepileptic, atypical antipsychotic, and carbapenem antibiotic. In addition, it offers veterinary medicines, medical devices, etc. The company has collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was formerly known as Sumitomo Dainippon Pharma Co., Ltd. and changed its name to Sumitomo Pharma Co., Ltd. in April 2022. The company was incorporated in 1897 and is headquartered in Osaka, Japan. Sumitomo Pharma Co., Ltd. is a subsidiary of Sumitomo Chemical Company, Limited.